文献速递胸部肿瘤

EGFR突变亚型影响晚期亚洲NSCLC患者一线吉非替尼治疗后的生存结局

EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients.
PubMed 文献 · J Thorac Oncol · 2016-11-28

研究纳入383例携带EGFR突变、接受一线吉非替尼治疗的IIIB或IV期亚洲NSCLC患者,评估EGFR突变类型与亚型对生存的影响。结果显示不同外显子突变患者PFS有显著差异,外显子19突变者中位PFS最长(总体p=8.88×10-15);OS在不同外显子间无显著差异(总体p=0.054),但外显子19各亚型间OS有显著差异,15核苷酸缺失「非ELREA」组OS最短为11.3个月(总体p=0.025)。

要点

  • 不同外显子(18、19、20、21)EGFR突变患者PFS有显著差异,外显子19突变者中位PFS最长。
  • 外显子19的5种突变亚型及2种缺失起始密码子间PFS无显著差异。
  • 不同外显子间OS无显著差异(总体p=0.054),但外显子19亚型间OS有显著差异。

核心结论

  • EGFR突变类型和亚型显著影响接受一线吉非替尼治疗的晚期NSCLC患者的生存结局。

研究设计与样本

  • 研究纳入383例IIIB或IV期、携带EGFR突变、接受一线吉非替尼治疗的亚洲NSCLC患者,采用Kaplan-Meier法估计OS和PFS,并用对数秩检验和Cox比例风险模型评估差异。

主要发现

  • 携带外显子18、19、20、21 EGFR突变患者之间PFS有显著差异,外显子19突变者中位PFS最长(总体p=8.88×10-15)。
  • 外显子19的5种突变亚型之间及2种外显子19缺失起始密码子之间PFS均无显著差异。
  • 不同外显子EGFR突变患者之间OS无显著差异(总体p=0.054)。
  • 外显子19各突变亚型之间OS有显著差异,15核苷酸缺失「非ELREA」组OS最短为11.3个月(总体p=0.025)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Activating mutations in the EGFR gene have been shown to confer sensitivity to EGFR tyrosine kinase inhibitors in patients with advanced NSCLC. However, wide interpatient variability in treatment outcomes in response to EGFR tyrosine kinase inhibitors in these patients remains unaccounted for. This study aimed to evaluate the influence of EGFR mutation types and subtypes on survival outcomes in advanced Asian patients with NSCLC receiving first-line gefitinib therapy. METHODS: Patients with stage IIIB or IV NSCLC who were harboring EGFR mutations, receiving first-line gefitinib treatment, and of Asian descent (N = 383) were evaluated. Overall survival (OS) and progression-free survival (PFS) were estimated by Kaplan-Meier analysis. Log-rank tests and Cox proportional hazards models were implemented to evaluate the differences in PFS and OS. RESULTS: Significant differences in PFS were observed between patients carrying EGFR mutations in exons 18, 19, 20, and 21, with patients carrying EGFR exon 19 mutations having the longest median PFS (overall p = 8.88 × 10-15). Comparison of PFS among the five different exon 19 mutation subtypes and among the two exon 19 deletion start codons did not reveal any significant differences. No significant difference was observed in OS among patients carrying EGFR mutations on different exons (overall p = 0.054); however, OS was found to be significantly different among the various subtypes of exon 19 mutations, with the 15-nucleotide deletion "non-ELREA" group having the shortest OS of 11.3 months (overall p = 0.025). CONCLUSIONS: EGFR mutation types and subtypes significantly influence survival outcomes in patients with advanced NSCLC who are receiving first-line gefitinib treatment.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Sutiman N, Tan SW, Tan EH, et al. EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients. J Thorac Oncol. 2016. PMID: 27908825. doi:10.1016/j.jtho.2016.11.2225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。